Literature DB >> 16862073

Inverted papilloma of the urinary bladder: a molecular genetic appraisal.

Ming-Tse Sung1, John N Eble, Mingsheng Wang, Puay-Hoon Tan, Antonio Lopez-Beltran, Liang Cheng.   

Abstract

Inverted papilloma of urinary bladder is an uncommon urothelial neoplasm. Its relationship to urothelial carcinoma is controversial. Little is known of the genetic abnormalities of inverted papilloma. To better understand its genetics, we analyzed 39 inverted papillomas, including 36 from men and three from women, for loss of heterozygosity (LOH). We examined four polymorphic microsatellite markers located on chromosome 9q32-33(D9S177), chromosome 9p22 (IFNA), chromosome 3p14.2 (D3S1300) and chromosome 17p13.1 (TP53), where genetic alterations occur frequently in urothelial carcinomas. Additionally, the status of inactivation of X-chromosome was examined in three female patients. The frequency of LOH in informative cases was 8% (3 of 37) for D9S177, 10% (4 of 38) for TP53, 8% (3 of 37) for IFNA and 8% (3 of 36) for D3S1300. In the analysis of X-chromosome inactivation, all three cases yielded informative results and one had nonrandom inactivation of X-chromosomes. The monoclonal origin demonstrated in the study of X-chromosome inactivation indicates the clonal process of inverted papilloma; however, the low incidence of LOH supports the view that inverted papilloma in urinary bladder is a benign neoplasm with molecular genetic abnormalities different from those of urothelial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862073     DOI: 10.1038/modpathol.3800667

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer.

Authors:  Barbara Domazet; Gregory T Maclennan; Antonio Lopez-Beltran; Rodolfo Montironi; Liang Cheng
Journal:  Int J Clin Exp Pathol       Date:  2008-03-15

2.  Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder.

Authors:  Eszter Székely; Péter Törzsök; Péter Riesz; Anna Korompay; Attila Fintha; Tamás Székely; Gábor Lotz; Péter Nyirády; Imre Romics; József Tímár; Zsuzsa Schaff; András Kiss
Journal:  J Histochem Cytochem       Date:  2011-08-10       Impact factor: 2.479

Review 3.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

4.  How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?

Authors:  Rodolfo Montironi; Liang Cheng; Marina Scarpelli; Roberta Mazzucchelli; Antonio Lopez-Beltran
Journal:  Diagn Pathol       Date:  2011-04-07       Impact factor: 2.644

5.  Immunohistochemistry and Fluorescence In Situ Hybridization Can Inform the Differential Diagnosis of Low-Grade Noninvasive Urothelial Carcinoma with an Inverted Growth Pattern and Inverted Urothelial Papilloma.

Authors:  Juan-Juan Sun; Yong Wu; Yong-Ming Lu; Hui-Zhi Zhang; Tao Wang; Xiao-Qun Yang; Meng-Hong Sun; Chao-Fu Wang
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  HRAS mutations are frequent in inverted urothelial neoplasms.

Authors:  Andrew S McDaniel; Yali Zhai; Kathleen R Cho; Saravana M Dhanasekaran; Jeffrey S Montgomery; Ganesh Palapattu; Javed Siddiqui; Todd Morgan; Ajjai Alva; Alon Weizer; Cheryl T Lee; Arul M Chinnaiyan; Michael J Quist; Catherine S Grasso; Scott A Tomlins; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-06-18       Impact factor: 3.466

7.  Expression pattern of p53-binding protein 1 as a new molecular indicator of genomic instability in bladder urothelial carcinoma.

Authors:  Katsuya Matsuda; Tatsuhiko Kawasaki; Yuko Akazawa; Yuhmi Hasegawa; Hisayoshi Kondo; Keiji Suzuki; Masachika Iseki; Masahiro Nakashima
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.